Ex Vivo Immune-Protein Profiling Supports First-Line JAK versus TNF Inhibitor Selection in biologic- and targeted synthetic DMARD-naïve Rheumatoid Arthritis patients (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2829; Pres time: Nov 10, 2026; 08:30 AM - 08:45 AM; Location: W304A-H; In Person; " Peripheral blood mononuclear cells and neutrophils from 48 b/tsDMARD-naïve RA patients were cultured with autologous serum and treated ex vivo with baricitinib or etanercept. Ex vivo-derived JAKi- and TNFi-modulated immune-protein signatures identify distinct b/tsDMARD-naïve RA subgroups with treatment-specific clinical outcomes. Their integration into a seven-protein machine-learning model provides a dual-therapy predictive framework that may support personalized first-line selection between JAKi and TNFi and reduce trial-and-error prescribing in RA. Funded by the EU/EFPIA Innovative Medicines Initiative Joint Undertaking 3TR, ISCIII (PI24/00959 and RD24/0007/0019, FI25/00087), and RYC2021-033828-I; co-financed by European Union."
IO biomarker • Preclinical • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CDCP1 • EIF4EBP1 • IL17C • PD-L1 • TGFB1
|
|
Sagrario Corrales Díaz-Flores1; Carlos Perez-Sanchez2; Tomás Cerdó3; Concepción Aranda-Valera4; Rafaela Ortega-Castro5; Jerusalem Calvo6; Christian Merlo7; Ismael Sanchez-Pareja8; Laura Muñoz-Barrera9; Maria Lourdes Ladehesa Pineda10; MºCarmen Ábalos-Aguilera11; Desirée Ruiz-Vilchez11; Nuria Barbarroja12; Samuel García13; Beatriz Malvar-Fernández13; Mº Ángeles Aguirre Zamorano14; Marta Alarcon-Riquelme15; Alejandro Escudero Contreras6; Chary Lopez-Pedrera16
|